Background {#Sec1}
==========

Noroviruses typically circulate from late fall through winter and causes gastrointestinal symptoms such as vomiting, diarrhea, and abdominal pain. The symptoms are generally mild and resolve within a few days. In older adults, however, norovirus infection can be serious and in some cases can lead to death from pulmonary aspiration of vomit. A 2016 review found hospitalization for norovirus and associated medical expenses and mortality rates are high in older adults \[[@CR1]\]. As Japan is rapidly becoming a "super-aging" society, measures to maintain the health of older people are crucial \[[@CR2]\]. However, there are currently no therapeutic medications for norovirus gastroenteritis, and symptomatic therapy is the main treatment. For these reasons, vaccines to prevent norovirus infection are under development \[[@CR3]\].

In order to introduce vaccines, accurate information about the disease burden of norovirus gastroenteritis is needed. In Japan, the incidence of infectious gastroenteritis can be estimated from disease surveillance data obtained as part of the National Epidemiological Surveillance of Infectious Diseases \[[@CR3]\]. However, the surveillance of infectious gastroenteritis is based on sentinel surveillance reports from pediatric hospital departments, and so it is not possible to estimate the potential number of older adults affected by norovirus. Furthermore, infectious gastroenteritis includes not only norovirus gastroenteritis, but also infections by other viruses such as rotavirus, adenovirus, and sapovirus, as well as bacterial infections \[[@CR4], [@CR5]\]. Consequently, the number of patients infected with each pathogen is unknown. Moreover, many cases of infectious gastroenteritis resolve within a few days so it is unusual for a diagnostic examination to be conducted in typical outpatient settings.

Therefore we conducted a nationwide epidemiologic study in Japan to assess the number of Japanese older adults hospitalized for infectious gastroenteritis and norovirus gastroenteritis and to clarify the clinical and epidemiologic features of these patients.

Methods {#Sec2}
=======

The study was conducted in accordance with existing procedures proposed by the Research Committee on Epidemiology of Intractable Diseases in Japan \[[@CR6]\]. The general method has been described previously \[[@CR7]--[@CR9]\]. The study consisted of two queries: the first intended to estimate the number of inpatients with infectious gastroenteritis among older adults, and the second to estimate the number of inpatients with norovirus gastroenteritis and to clarify their clinical and epidemiologic features.

First query {#Sec3}
-----------

A number of hospital departments were selected using stratified random sampling from a total of 17,575 departments of internal medicine, digestive diseases, gastroenterology, respiratory diseases, and cardiovascular diseases nationwide. These are the departments in which older people with aggravated infectious gastroenteritis predominantly receive treatment in Japan. The sampling was stratified by the number of hospital beds; sampling proportions were as follows: general hospitals with 99 beds or fewer, 5%; 100--199 beds, 10%; 200--299 beds, 20%; 300--399 beds, 40%; 400--499 beds, 80%; 500 beds or more, 100%; and university hospitals, 100%. A final total of 4184 departments were selected (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

In January 2016, we asked these departments to complete a mail-back questionnaire, which was designed to ascertain the presence or absence of hospitalized patients with infectious gastroenteritis among adults aged ≥60 years between administrative years 2012 and 2014 (i.e., between April 1, 2012, and March 31, 2015). The information of the hospitalized patients included both community-acquired infection and nosocomial infection. We obtained data by administrative year, as hospital reporting is typically done in this manner in Japan. If present, the number of inpatients and deaths in each administrative year were additionally solicited. We also collected information on whether norovirus tests were routinely conducted at the department (routinely conducted, often conducted, or not conducted). A reminder was mailed to non-respondents in April 2016.

Second query {#Sec4}
------------

In September 2016, we sent a second query to departments that had responded "yes" to the presence of patients hospitalized for infectious gastroenteritis in the first query. The second query was to collect data on the numbers of inpatients and deaths of those diagnosed with norovirus gastroenteritis among adults aged ≥60 years between administrative years 2012 and 2014. Determination of norovirus gastroenteritis depended on the physician's diagnosis of each hospital. Clinical diagnosis without viral examination such as possible epidemiological link was allowed for counting number of norovirus gastroenteritis. To take into account the nosocomial infected cases, cases of norovirus gastroenteritis diagnosed not only at admission but also during the hospital stay were included. For patients hospitalized in administrative year 2014, the following clinical information was also collected: birth month and birth year, sex, residence at the onset of gastroenteritis (i.e., home, long-term care facility, or hospital), underlying diseases (hypertension, heart disease, diabetes, stroke, malignant tumor, renal disease, chronic respiratory disease, liver disease, hematological disorders, or collagen diseases), date of admission, date of discharge, possible cause of infection based on the physician's medical examination including interview to the patients (contaminated food, contact with infected person(s), disease epidemic in the area), results of tests for norovirus, clinical symptoms (presence, frequency, and duration of diarrhea and vomiting; presence of fever), date of symptom onset and duration, complicated diseases (such as aspiration pneumonia), laboratory data at the time of admission, treatment (e.g., intravenous drip, antibiotics, and intensive care unit therapy), clinical outcome (recovered, moved to another hospital, self-discharged, or deceased), and cause of death if deceased. We assumed that the clinical information of norovirus gastroenteritis did not change significantly between administrative years 2012 and 2014, and due to research budget constraints we did not obtain the clinical information for patients hospitalized in administrative years 2012 and 2013, but choose to investigate the latest information available, i.e. in administrative year 2014. We confirmed our assumption that the epidemic trend of norovirus infection in the three administrative years was stable in Japan using national surveillance data \[[@CR10]\]. We mailed a reminder to non-respondents in November 2016. Additionally, we asked the departments that had responded to confirm or revise those parts of the previously returned questionnaire that had missing or conflicting information. If there were missing data even after confirmation or revision, the data were considered incomplete.

Statistical analysis {#Sec5}
--------------------

Accounting for sampling and response proportions in the first query, we estimated the total numbers of inpatients and deaths due to infectious gastroenteritis among adults aged ≥60 years between administrative years 2012 and 2014 according to the following formula: estimated total number of inpatients = reported number of inpatients / (sampling proportion × response proportion). Additionally, 95% confidence intervals (CIs) were calculated with an assumption of multinomial hypergeometric distribution \[[@CR6]--[@CR9]\].

We also estimated the total numbers of inpatients and deaths due to norovirus gastroenteritis among adults aged ≥60 years between administrative years 2012 and 2014 using data from the second query. In this calculation, we used the following formula: estimated total number of inpatients with norovirus gastroenteritis = estimated total number of inpatients with infectious gastroenteritis × proportion of reported number of inpatients with norovirus gastroenteritis among the reported number of inpatients with infectious gastroenteritis. This latter proportion was based on information from departments that responded to the second query. Total estimated numbers and 95% CIs were rounded to three significant digits, except for the hundreds, which were rounded to two significant digits.

Hospitalization and mortality rates in each administrative year were calculated using the number of Japanese people aged ≥60 years at October 1 in each administrative year (i.e., 41,038,000 in administrative year 2012, 41,561,000 in administrative year 2013, and 41,980,000 in administrative year 2014) \[[@CR11]--[@CR13]\].

The clinical characteristics of inpatients with norovirus gastroenteritis were also examined. Age at admission was calculated using information on birth month and birth year and date of admission. If the admission date had not been recorded, it was regarded as October 1 for the calculation. Disease severity was assessed using modified Vesikari scores \[[@CR14]\]. In order to assess the disease severity using laboratory data such data were categorized into two or three levels according to standard values for the Japanese population \[[@CR15]\]. To examine factors associated with death, a logistic regression model was used to obtain odds ratios (ORs) and 95% CIs. Since age and sex are the important predictors for death, these variables were included as co-factors in a logistic regression model.

All tests were two-sided. All analyses were performed using SAS version 9.3 software (SAS Institute, Cary, NC, USA).

Results {#Sec6}
=======

In the first query, 1325 out of 4184 departments responded (response proportion: 31.7%). Among these, 561 departments reported the presence of inpatients with infectious gastroenteritis; numbers of reported inpatients were 9857 in administrative year 2012, 8361 in administrative year 2013, and 8410 in administrative year 2014 (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The response rates from gastroenterology departments in large hospitals were low (e.g. 20% in five University hospitals, 0% in four ≥500 beds hospitals). Since there were only nine gastroenterology departments, the low response rate did not have a major impact on the present results (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Based on the results of the first query, the numbers of inpatients with infectious gastroenteritis among Japanese adults aged ≥60 years were estimated to be 118,000 (95% CI: 95,700--141,000) in administrative year 2012, 95,100 (95% CI: 77,700--112,000) in administrative year 2013, and 96,900 (95% CI: 79,500--114,000) in administrative year 2014. Infectious gastroenteritis was estimated to have caused 2060 (95% CI: 1370--2750), 1940 (95% CI: 1230--2640), and 1970 (95% CI: 1280--2650) deaths among Japanese adults aged ≥60 years in administrative years 2012, 2013, and 2014, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Estimated number of hospitalized patients and deaths due to infectious gastroenteritis among adults aged ≥60 years in JapanStratum (No. of hospital beds)Administrative year 2012Administrative year 2013Administrative year 2014Hospitalized patientsDeathsHospitalized patientsDeathsHospitalized patientsDeathsUniversity hospital136616125130111914≥500950246981524617684415400--499915218177971808310182300--39920,87947017,91944819,072583200--29918,36513315,64011915,200191100--19939,12066128,28969727,879512\< 9920,05613016,012017,63274Total estimated number118,000206095,100194096,9001970(95% confidence interval)(95,700--141,000)(1370--2750)(77,700--112,000)(1230--2640)(79,500--114,000)(1280--2650)

In the second query, 271 out of 561 departments responded (response proportion: 48.0%), and 126 departments reported the presence of inpatients with norovirus gastroenteritis. Among these departments, the proportions of reported number of inpatients with norovirus gastroenteritis among the reported number of inpatients with infectious gastroenteritis were 26.9% in administrative year 2012, 22.7% in administrative year 2013, and 16.2% in administrative year 2014. Thus, the estimated numbers of inpatients with norovirus gastroenteritis among Japanese adults aged ≥60 years were calculated as 31,800 (95% CI: 25,700--37,900) in administrative year 2012, 21,600 (95% CI: 17,700--25,500) in administrative year 2013, and 15,700 (95% CI: 12,900--18,500) in administrative year 2014 (Table [2](#Tab2){ref-type="table"}). The hospitalization rates (per 10,000 persons) were 7.75, 5.20, and 3.74, respectively. Among the reported number of deaths from infectious gastroenteritis 31.3% in administrative year 2012, 30.0% in administrative year 2013, and 29.6% in administrative year 2014 were due to norovirus, and norovirus gastroenteritis was estimated to have caused a total of 650 (95% CI: 430--860), 580 (95% CI: 370--790), and 580 (95% CI: 380--790) deaths in administrative years 2012, 2013, and 2014, respectively (Table [2](#Tab2){ref-type="table"}). The respective mortality rates (per 100,000 persons) were 1.58, 1.40, and 1.38.Table 2Estimated number of hospitalized patients and deaths due to norovirus gastroenteritis among adults aged ≥60 years in JapanStratum (No. of hospital beds)Administrative year 2012Administrative year 2013Administrative year 2014Hospitalized patientsDeathsHospitalized patientsDeathsHospitalized patientsDeathsUniversity hospital367528491814≥500255214718531381246123400--499245857177254134754300--399560814740721353092172200--299493242355436246456100--19910,50720764292094519151\< 9953874136390285822Total estimated number31,80065021,60058015,700580(95% confidence interval)(25,700--37,900)(430--860)(17,700--25,500)(370--790)(12,900--18,500)(380--790)

Figure [1](#Fig1){ref-type="fig"} shows the implementation status of norovirus infection testing in Japanese hospitals. Approximately 15.8% of departments replied that norovirus testing (mainly rapid antigen testing) was "routinely conducted" for patients hospitalized for acute gastroenteritis; 49.7% of departments responded that such testing was "often conducted", which means that some acute gastroenteritis inpatients received norovirus testing but other acute gastroenteritis inpatients did not; 22.9% of departments did not conduct norovirus tests for patients hospitalized for gastroenteritis. In particular, university hospitals or general hospitals with larger numbers of beds tended to respond "not conducted."Fig. 1Implementation status of norovirus infection testing at university hospitals and general hospitals according to number of hospital beds. According to answers of "unknown data", each total has not reached 100%

Table [3](#Tab3){ref-type="table"} summarizes the clinical characteristics of inpatients with norovirus gastroenteritis in administrative year 2014. Male patients accounted for 42% of inpatients. Approximately 55% of patients were aged ≥80 years. Most patients (90%) had underlying illnesses. Regarding the possible cause of infection, only 9% were suspected to be caused by contaminated food, and 21% were presumably caused by contact with an infected person considered to be possible epidemiological link. However, the cause was not known for about half of the patients. Only 61% of inpatients received norovirus testing. Among those, half had positive results. Most patients had diarrhea and half had symptoms of vomiting or fever. Approximately 6% of cases were complicated by aspiration pneumonia. The median duration of hospital admission was 11 days; although 93% of patients recovered, 4% died. The main cause of death was pneumonia (*n* = 7). Other causes were as follows: heart failure (*n* = 4), malignant tumor (n = 4), and ileus, digestive tract hemorrhage, respiratory failure, multi-organ failure, and perforation of the digestive tract (*n* = 1 each).Table 3Characteristics of patients hospitalized for norovirus gastroenteritis (*N* = 470)Characteristicsn (%) or\
median (range)^a^Characteristicsn (%) or\
median (range)^a^SexMale194 (42)Laboratory data at the time of admissionAge (years)60--6966 (14) White blood cell (/μL)Decreased17 (4)70--79145 (31)Normal231 (51)≥80259 (55)Increased202 (45)Residence at symptom onset Hemoglobin (g/dL)Decreased190 (42)Home287 (62)Normal249 (55)Long-term care facility62 (13)Increased17 (4)Hospital115 (25) Platelet count (× 10^4^/μL)Decreased47 (10)Underlying illnesses424 (90)Normal386 (84)Hypertension213 (45)Increased28 (6)Heart disease121 (26) C-reactive protein (mg/dL)Increased349 (77)Diabetes106 (23) Blood sugar (mg/dL)Decreased18 (5)Stroke121 (26)Normal102 (26)Malignant tumor66 (14)Increased268 (69)Renal disease38 (8) Albumin (g/dL)Decreased230 (59)Chronic respiratory disease32 (7) Aspartate aminotransferase (IU/L)Increased205 (45)Liver disease24 (5) Creatinine (mg/dL)Increased200 (44)Hematological disorders13 (3) Sodium (mEq/L)Decreased81 (18)Collagen diseases7 (1)Normal375 (82)Possible causes of infectionIncreased4 (1)Contaminated food43 (9) Potassium (mEq/L)Decreased106 (23)Contact with infected person(s)95 (21)Normal329 (72)Disease epidemic in the area99 (21)Increased24 (5)Tested for norovirus287 (61) Chloride (mEq/L)Decreased54 (12) Test resultPositive153 (53)Normal376 (83)Clinical symptoms at the time of admissionIncreased23 (5) DiarrheaPresent377 (80)TreatmentDuration (days)4 (1--36)^a^ Intravenous drip386 (82)Frequency per day3.5 (1--33)^a^ Antibiotics201 (43) VomitingPresent232 (49) Oxygen supplementation73 (16)Duration (days)2 (1--14)^a^ Intensive care unit therapy10 (2)Frequency per day1.5 (1--25)^a^ Use of respirator7 (1) FeverPresent262 (56)Duration of hospital admission (days)11 (1--2359)^a^Maximum fever (°C)37.85 (37.0--40.3)^a^Clinical outcomeRecovered438 (93)ComplicationsAspiration pneumonia28 (6)Moved to hospital10 (2)Others35 (8)Deceased21 (4)Modified Vesikari scale8 (0--16)^a^Self-discharged1 (0.2)^a^median (range)

Higher mortality in 470 clinical diagnosed cases was observed among males, older patients, those living in long-term care facilities, those with particular underlying illnesses such as chronic respiratory diseases, and those with complications such as aspiration pneumonia (Table [4](#Tab4){ref-type="table"}). Female patients had a significantly decreased adjusted OR (aOR) for death compared with male patients (aOR = 0.41, 95% CI: 0.16--1.00). Moreover, those living in long-term care facilities (aOR = 3.39, 95% CI: 1.15--9.55), those with chronic respiratory diseases (aOR = 3.90, 95% CI: 1.01--12.5), and those with aspiration pneumonia (aOR = 8.97, 95% CI: 3.06--24.7) had significantly increased aORs for death.Table 4Association between selected background characteristics and death from norovirus gastroenteritis^a^CharacteristicsMortalityUnivariate analysisAge/sex-adjusted analysisn/N (%)OR (95% CI)aOR (95% CI)SexMale12/194 (6)1.001.00Female9/273 (3)0.52 (0.21--1.25)0.41 (0.16--1.00)Age (years)60--692/66 (3)1.001.0070--793/145 (2)0.68 (0.11--5.22)0.69 (0.11--5.35)≥8016/259 (6)2.11 (0.58--13.5)2.63 (0.71--17.1)(Trend *P* = 0.11)(Trend *P* = 0.05)Residence at symptom onsetHome11/287 (4)1.001.00Long-term care facility7/62 (11)3.19 (1.13--8.48)3.39 (1.15--9.55)Hospital3/115 (3)0.67 (0.15--2.20)0.67 (0.15--2.22)Underlying illnessesAbsent1/45 (2)1.001.00Present20/424 (5)2.18 (0.44--39.5)2.16 (0.43--39.4) Chronic respiratory diseaseAbsent17/438 (4)1.001.00Present4/32 (13)3.54 (0.97--10.4)3.90 (1.01--12.5) Collagen diseasesAbsent20/463 (4)1.001.00Present1/7 (14)3.69 (0.19--23.1)4.11 (0.21--28.1) Hematological disordersAbsent19/457 (4)1.001.00Present2/13 (15)4.19 (0.62--17.1)4.40 (0.64--18.9)Complications Aspiration pneumoniaAbsent14/439 (3)1.001.00Present7/28 (25)10.1 (3.53--27.2)8.97 (3.06--24.7) OthersAbsent15/427 (4)1.001.00Present6/35 (17)5.68 (1.91--15.2)5.42 (1.79--14.8)*Abbreviations*: *OR* odds ratio, *aOR* adjusted odds ratio, *CI* confidence interval^a^Logistic regression model

Discussion {#Sec7}
==========

The results of our study suggest that approximately 100,000 persons aged ≥60 years are hospitalized for infectious gastroenteritis annually in Japan, of which approximately one-quarter are hospitalized for norovirus gastroenteritis. The number of inpatients with norovirus gastroenteritis was approximately 15,000 in administrative year 2014 (when the disease occurred at a low rate) and approximately 30,000 in administrative year 2012 (when it became epidemic, with approximately 600 annual deaths). The annual hospitalization rate (per 10,000 population) for norovirus gastroenteritis was 3.74--7.75 and the annual mortality rate (per 100,000 population) was 1.38--1.58 among persons aged ≥60 years. However, since the proportion of departments which routinely conducted norovirus testing for acute gastroenteritis inpatients was lower than expected, the actual number of norovirus inpatients would be higher than the estimated number here.

The present study showed a large number of inpatients in administrative year 2012 and relatively few inpatients in administrative year 2014, and this trend was consistent with the National Surveillance Data of infectious gastroenteritis patients reported by sentinels \[[@CR4]\]. Additionally, the proportion of norovirus inpatients among infectious gastroenteritis inpatients in the present study (16--27%) was similar to that reported in a meta-analysis of 175 research papers (17--20%) \[[@CR16]\]. However, the proportion was somewhat lower than the proportions reported by other studies in Japan (34--39%) \[[@CR17]--[@CR19]\]. As norovirus gastroenteritis is an infectious disease, its epidemic status varies between geographical regions. It is possible therefore that the differences in the proportion of norovirus patients between the present study and other studies in Japan merely indicate differences in epidemic status among geographical regions.

In Japan, norovirus testing is not routinely conducted by all hospitals so it is possible that the results of our study were influenced by the status of implementation of testing at the hospitals that were surveyed. In fact, institutions not testing for norovirus accounted for one-quarter of the hospitals that were studied. In the present study, it is possible that such institutions reported having no inpatients with norovirus gastroenteritis. Therefore, the present data may underestimate the annual number of inpatients with norovirus gastroenteritis and also the proportion of nosocomial infection. In addition, university hospitals or general hospitals with larger numbers of beds tended to report that they had not conducted norovirus testing. We assumed that these hospitals were more likely to contain patients with infectious gastroenteritis and assigned a higher sampling proportion to these hospitals in the study protocol. However, the unexpectedly lower implementation status of norovirus testing might have affected the study results. One study that estimated the burden of norovirus gastroenteritis in Japan using a modelling approach accounting for the absence of routine diagnostic testing showed higher incidence rates in the elderly than our study \[[@CR20]\]. However, the database used in that study had relatively few older adults and therefore may not have been representative of the Japanese population. Compared with the previous study, our findings seem to suggest a lower norovirus disease burden in older adults according to laboratory-confirmed cases. This represents a possible limitation of our study in that many hospitals did not conduct norovirus testing. Another limitation was a lower response proportion to the first query (31.7%), which may have introduced bias. According to a nationwide epidemiologic investigation manual issued by the Japanese Ministry of Health, Labour and Welfare \[[@CR5]\], a response proportion of approximately 60% can produce a reliable estimation of number of patients; however, we did not obtain this response proportion. If non-response were associated with nosocomial norovirus infection due to the hesitancy to disclose negative clinical practice in hospitals, the present results might be biased. In general, however, medical institutes that are highly conscious of measures against infectious diseases, such as having their own manual for infectious diseases, are likely to have responded in our study, and their responses seemed to be highly reliable. On the other hand, in the non-response departments, norovirus gastroenteritis may not be sufficiently understood. In the present study protocol, assuming that non-response departments had a similar proportion of inpatients with norovirus gastroenteritis as those departments which responded, we estimated the number of inpatients or deaths with norovirus gastroenteritis in Japan. However, we cannot deny the possibility that precision of the present results may be low, although we believe that the present results may be validated.

The annual hospitalization and mortality rates for norovirus gastroenteritis in the present study are similar to those in other countries. A systematic review of 39 studies in adults aged \> 65 years worldwide reported the hospitalization rate for norovirus gastroenteritis as 1--19 per 10,000 persons and the mortality rate as 0.4--3.2 per 100,000 persons \[[@CR21]\]. Our results fall within these ranges. The systematic review also reported the annual rate of outpatient visits for norovirus gastroenteritis as 18--54 per 10,000 persons and the annual incidence rate as 29--125 per 10,000 persons. In this study, we did not obtain information on outpatient visits and incidence; thus, we cannot compare these rates. If the results of the systematic review are applied to Japan, the number of outpatient visits for norovirus gastroenteritis among the population aged ≥60 years (42.75 million, October 2016) would be estimated at 76,950--230,850, and the annual number of incident cases would be estimated at 123,975--534,375, suggesting that norovirus gastroenteritis has a substantial influence on the health of Japanese older adults.

We found that the possible cause of norovirus gastroenteritis was consumption of contaminated food in 9% of inpatients and person-to-person transmission in 21%. Compared with an outbreak investigation conducted in Spain, the present study found a higher proportion of cases of unknown cause; in the Spanish outbreak investigation, 42% of cases were probably caused by consumption of contaminated food and 52% were likely caused by person-to-person transmission \[[@CR22]\]. The present results highlight the difficulties in determining the cause of norovirus gastroenteritis infection occurring in the community.

Regarding clinical symptoms, diarrhea was reported in 80% of cases, vomiting in 49%, and fever in 56%. These proportions are lower than those reported in pediatric studies. In young children in an Israeli study diarrhea was reported in 81%, vomiting in 86%, and fever in 64% of patients \[[@CR23]\]. Disease severity was lower in the present study than in a study of young children conducted in Taiwan, which reported a median Vesikari value of 12.5 \[[@CR24]\]. However, intravenous drip was more often administered to inpatients in the present study compared with children in the Israeli study (82% vs. 68%) \[[@CR23]\]. The median duration of hospital admission was longer in the present study compared with children in the Taiwanese study (11 days vs. 3 days) \[[@CR24]\]. Differences in treatment may simply reflect differences in medical care between study regions. Nonetheless, the present results also suggest that, compared with children, older adults tend to experience more dehydration and require more time to recover. Such information may be important when the disease burden of norovirus gastroenteritis is considered from a medical economics perspective.

In our study, 4% of hospitalized patients died. Factors associated with death include greater age, living in long-term care facilities, underlying illnesses (particularly chronic respiratory diseases), and complications such as aspiration pneumonia. In a study of 1877 cases in an outbreak of norovirus gastroenteritis in England and Wales between 1992 and 2000, all deaths from norovirus gastroenteritis occurred in patients who were hospitalized or institutionalized \[[@CR25]\]. A systematic review of reports from 1988 to 2011 found more deaths among older adults, those living in long-term care facilities, and those in an immunosuppressed state, and the most common cause of death was aspiration pneumonia (32%) \[[@CR26]\]. Older adults with underlying illnesses (particularly chronic respiratory diseases) are considered to be highly susceptible to infectious diseases, which may lead to a high risk of death when norovirus gastroenteritis develops as a complication. Taken together, the factors associated with death in the present study are consistent with these previous reports. Therefore, we hope that these results will provide useful information for the future introduction of vaccine measures.

Conclusions {#Sec8}
===========

In conclusion, although the actual number of norovirus inpatients is probably higher than the estimates here due to the low rate of routinely implemented norovirus testing, the annual number of patients hospitalized for norovirus gastroenteritis was estimated to range from 15,700 (administrative year 2014) to 31,800 (administrative year 2012), and the annual number of deaths was estimated to be between 580 (administrative years 2013, 2014) and 650 (administrative year 2012). The annual hospitalization rate was 3.74 (administrative year 2014) to 7.75 (administrative year 2012) per 10,000 persons, and the annual mortality rate was 1.38 (administrative year 2014) to 1.58 (administrative year 2012) per 100,000 persons. The factors associated with death among inpatients with norovirus gastroenteritis included higher age, living in long-term care facilities, underlying illnesses (particularly chronic respiratory diseases), and complications such as aspiration pneumonia. Considering Japan's rapidly aging society and the disease burden of norovirus infection among Japanese older adults, it is important to protect this high-risk population from norovirus infection.
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